Analysts See $0.48 EPS for CNB Financial (CCNE); 9 Analysts Are Bullish Akebia Therapeutics, Inc. (AKBA) Last Week

Friday, 30 March 2018

Analysts See $0.48 EPS for CNB Financial (CCNE); 9 Analysts Are Bullish Akebia Therapeutics, Inc. (AKBA) Last Week

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Logo

Analysts expect CNB Financial Corporation (NASDAQ:CCNE) to report $0.48 EPS on April, 16.They anticipate $0.05 EPS change or 11.63% from last quarter’s $0.43 EPS. CCNE’s profit would be $7.34 million giving it 15.15 P/E if the $0.48 EPS is correct. After having $0.43 EPS previously, CNB Financial Corporation’s analysts see 11.63% EPS growth. The stock decreased 0.95% or $0.28 during the last trading session, reaching $29.09. About 17,388 shares traded. CNB Financial Corporation (NASDAQ:CCNE) has risen 18.14% since March 30, 2017 and is uptrending. It has outperformed by 6.59% the S&P500.

Among 11 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Akebia Therapeutics Inc had 25 analyst reports since August 13, 2015 according to SRatingsIntel. Brean Capital maintained Akebia Therapeutics, Inc. (NASDAQ:AKBA) on Thursday, August 13 with “Buy” rating. The rating was maintained by Mizuho with “Buy” on Wednesday, March 7. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. As per Friday, June 30, the company rating was maintained by Aegis Capital. Brean Capital maintained the stock with “Buy” rating in Wednesday, September 9 report. H.C. Wainwright maintained the shares of AKBA in report on Tuesday, June 6 with “Buy” rating. RBC Capital Markets maintained the stock with “Hold” rating in Thursday, November 2 report. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) has “Overweight” rating given on Wednesday, September 9 by Morgan Stanley. On Tuesday, November 15 the stock rating was initiated by Aegis Capital with “Buy”. The rating was initiated by BTIG Research with “Buy” on Thursday, December 7. See Akebia Therapeutics, Inc. (NASDAQ:AKBA) latest ratings:

07/03/2018 Broker: Mizuho Rating: Buy New Target: $24.0 Maintain
18/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Initiate
07/12/2017 Broker: BTIG Research Rating: Buy New Target: $30.0 Initiate
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $17.0 Maintain
04/10/2017 Broker: Mizuho Rating: Buy New Target: $24.0 Initiate

Since December 15, 2017, it had 3 buys, and 2 selling transactions for $43,446 activity. Scott Nicholas N. Jr. also bought $911 worth of CNB Financial Corporation (NASDAQ:CCNE) on Friday, December 15. Peterson Joel E. sold $60,426 worth of stock. 413 shares valued at $12,175 were sold by BREAKEY MARK D on Monday, March 12. $26,910 worth of CNB Financial Corporation (NASDAQ:CCNE) shares were bought by Straub Francis X III.

Investors sentiment decreased to 1.28 in Q4 2017. Its down 0.08, from 1.36 in 2017Q3. It dropped, as 4 investors sold CNB Financial Corporation shares while 21 reduced holdings. 11 funds opened positions while 21 raised stakes. 6.36 million shares or 2.84% less from 6.55 million shares in 2017Q3 were reported. Cornercap Counsel holds 0.1% or 28,010 shares in its portfolio. 28,261 are held by Schwab Charles Investment Management. Renaissance Techs Lc invested in 0.01% or 220,300 shares. 88 are owned by Sei Investments Com. California State Teachers Retirement Systems owns 0% invested in CNB Financial Corporation (NASDAQ:CCNE) for 23,281 shares. Martingale Asset Ltd Partnership owns 71,732 shares. Strs Ohio accumulated 0% or 25,600 shares. Dimensional Fund Advsrs Ltd Partnership reported 439,063 shares or 0% of all its holdings. Maltese Ltd Liability Co holds 0% or 800 shares. Connors Investor Svcs reported 0.06% of its portfolio in CNB Financial Corporation (NASDAQ:CCNE). Moreover, Bryn Mawr Communications has 0.03% invested in CNB Financial Corporation (NASDAQ:CCNE) for 20,966 shares. 15,024 are held by Rhumbline Advisers. Prudential Financial Incorporated reported 0% in CNB Financial Corporation (NASDAQ:CCNE). Pnc Fin Serv Grp has 12,070 shares. State Street holds 257,423 shares or 0% of its portfolio.

CNB Financial Corporation operates as the bank holding firm for CNB Bank that provides various banking services and products for individual, business, governmental, and institutional customers. The company has market cap of $444.62 million. The companyÂ’s principal services and products comprise checking, savings, and time deposit accounts; and real estate, commercial, industrial, residential, and consumer loans. It has a 18.55 P/E ratio. It also offers various other specialized financial services; and trust and asset management services, including the administration of trusts and estates, retirement plans, and other employee benefit plans, as well as a range of wealth management services.

The stock decreased 2.16% or $0.21 during the last trading session, reaching $9.53. About 874,458 shares traded or 117.91% up from the average. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has risen 5.85% since March 30, 2017 and is uptrending. It has underperformed by 5.70% the S&P500.

Investors sentiment decreased to 1.63 in 2017 Q4. Its down 0.60, from 2.23 in 2017Q3. It fall, as 15 investors sold Akebia Therapeutics, Inc. shares while 28 reduced holdings. 26 funds opened positions while 44 raised stakes. 30.27 million shares or 5.16% more from 28.78 million shares in 2017Q3 were reported. Goldman Sachs Grp has invested 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Manufacturers Life Insur The has invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). 135,738 are owned by Dafna Management Lc. 513,456 are held by Northern Tru. Moreover, Landscape Cap Mngmt Limited Liability Corporation has 0.05% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Credit Suisse Ag has invested 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Alps Advisors holds 0.01% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 52,379 shares. Creative Planning holds 0% or 10,650 shares. Johnson Inv Counsel invested in 61,462 shares. Us Fincl Bank De invested 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Bancorp Of Mellon accumulated 251,393 shares. Lpl Finance reported 23,559 shares. Millennium Limited reported 0.02% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Massachusetts-based Amundi Pioneer Asset Incorporated has invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Deutsche Natl Bank Ag reported 161,640 shares.

CNB Financial Corporation (NASDAQ:CCNE) Institutional Positions Chart